Barclays PLC Lowers Holdings in Cardiovascular Systems Inc (CSII)

Barclays PLC cut its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 31.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,161 shares of the medical device company’s stock after selling 10,975 shares during the quarter. Barclays PLC owned about 0.07% of Cardiovascular Systems worth $688,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quantamental Technologies LLC purchased a new position in Cardiovascular Systems during the 4th quarter worth approximately $37,000. Paloma Partners Management Co purchased a new position in Cardiovascular Systems during the 3rd quarter worth approximately $202,000. Janus Henderson Group PLC purchased a new position in Cardiovascular Systems during the 3rd quarter worth approximately $202,000. Ibex Investors LLC purchased a new position in Cardiovascular Systems during the 3rd quarter worth approximately $219,000. Finally, Pura Vida Investments LLC purchased a new position in Cardiovascular Systems during the 4th quarter worth approximately $227,000. Institutional investors and hedge funds own 84.54% of the company’s stock.

A number of research analysts recently issued reports on CSII shares. BidaskClub downgraded Cardiovascular Systems from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. ValuEngine upgraded Cardiovascular Systems from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 5th. Zacks Investment Research downgraded Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Friday, March 15th. Finally, Bank of America downgraded Cardiovascular Systems from a “buy” rating to an “underperform” rating and set a $42.00 target price on the stock. in a research note on Thursday, April 11th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $44.00.

Shares of CSII traded up $0.23 during mid-day trading on Friday, hitting $34.16. The company’s stock had a trading volume of 426,224 shares, compared to its average volume of 358,750. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.38 and a quick ratio of 3.88. The stock has a market capitalization of $1.19 billion, a P/E ratio of 683.20 and a beta of 2.16. Cardiovascular Systems Inc has a 1-year low of $21.88 and a 1-year high of $42.64.

Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings data on Wednesday, January 30th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.05. The firm had revenue of $60.21 million during the quarter, compared to analysts’ expectations of $59.66 million. Cardiovascular Systems had a return on equity of 1.28% and a net margin of 0.74%. Research analysts anticipate that Cardiovascular Systems Inc will post -0.1 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/barclays-plc-has-688000-position-in-cardiovascular-systems-inc-csii.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Read More: How accurate is the Rule of 72?

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.